Inhibition of EP4 activation aggravated AKI-to-CKD transition, whereas, pharmacologically promoting EP4 activation remarkably ameliorated AKI and its progression to CKD though regulating macrophage polarization. Here, PTGER4 is linked to chronic kidney disease.